CellSight Technologies, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: San Francisco CA United States (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2015
NCT02323893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CellSight Technologies, Inc.